Asn51, An Orally Bioavailable Small-Molecule O-Glcnacase Inhibitor, Has Both Immediate And Disease-Modifying Benefits In Preclinical Models Of Parkinson'S Disease And Epilepsy
ANNALS OF NEUROLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要